Quick Answer
Connect Biopharma Holdings Ltd reported R&D Expense of $37.80 million for fiscal year 2025.
Connect Biopharma Holdings Ltd R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $37.80M | +29.2% |
| 2024 | $29.26M | -44.8% |
| 2023 | $53.00M | -45.1% |
| 2022 | $96.63M | +20.0% |
| 2021 | $80.50M | -46.7% |
| 2020 | $150.93M | +41.8% |
| 2019 | $106.41M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.11M | +23.3% | +26.6% |
| June 30, 2025 | $8.77M | +64.0% | +32.3% |
| March 31, 2025 | $6.63M | -23.4% | -26.4% |
| September 30, 2024 | $9.01M | — | +68.5% |
| June 30, 2024 | $5.35M | — | -38.3% |
| March 31, 2024 | $8.66M | — | — |
- Connect Biopharma Holdings Ltd showed an increase of +29.2% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Connect Biopharma Holdings Ltd’s r&d expense has declined by 64.5% (from $106.41 million to $37.80 million).
- The most recent figure is from Connect Biopharma Holdings Ltd’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: